CAR-TCR 2023 – Tim McGuire
As the cell therapy world has heated up, so too has the world of cell and gene therapy contract manufacturing. But as rife as that space is with opportunities, it’s also rife with challenges.
At CAR-TCR last month in Boston, pharmaphorum editor-in-chief Jonah Comstock grabbed some time with Tim McGuire, director of business development at biomanufacturer Resilience.
They discuss some of the ways Resilience seeks to stand out from an increasingly crowded field of competitors, including clinical partnerships with the likes of MD Anderson Cancer Center, a willingness to work with all kinds of clients from early-stage biotech to big pharma, and a willingness to engage with different business models to help partners solve funding problems.
Tim also shares his perspective into the future of the space, including innovations that need to happen in manufacturing speed, how the shift from autologous to allogeneic therapies is likely to play out, and what else is on the horizon – including the possibilities of in vivo gene editing and how it could transform the biomanufacturing market.
Check out the video below for a peak into the future of cell therapy manufacturing.
